Quince Therapeutics Inc
QNCX
Company Profile
Business description
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Contact
611 Gateway Boulevard
Suite 273
South San FranciscoCA94080
USAT: +1 415 910-5717
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
38
Stocks News & Analysis
stocks
Is SpaceX a threat to this ASX giant?
Investors are raising concerns about the future of telecommunication connectivity in Australia.
stocks
Chart of the Week: This ASX top pick might be overlooked
ASX top pick remains cheap as investor concerns around wage costs might be overdone.
stocks
ASX share undervalued as margins expected to rebound
This ASX share remains overlooked despite a strong outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,126.80 | 39.10 | -0.43% |
| CAC 40 | 8,467.98 | 37.19 | 0.44% |
| DAX 40 | 25,026.80 | 92.13 | 0.37% |
| Dow JONES (US) | 51,564.70 | 72.15 | 0.14% |
| FTSE 100 | 10,399.70 | 108.91 | -1.04% |
| HKSE | 23,924.81 | 387.35 | -1.59% |
| NASDAQ | 26,517.93 | 496.28 | 1.91% |
| Nikkei 225 | 71,053.49 | 1,151.24 | 1.65% |
| NZX 50 Index | 13,410.67 | 47.36 | 0.35% |
| S&P 500 | 7,500.58 | 80.48 | 1.08% |
| S&P/ASX 200 | 8,911.10 | 37.60 | -0.42% |
| SSE Composite Index | 4,090.48 | 17.59 | -0.43% |